Fenestra HDVC is a non-toxic contrast agent for small animal in vivo microCT imaging.
Micro-computed tomography (micro-CT) imaging has been used to analyze organs in experimental subjects however, it often requires contrast agents in order to better visualize the soft tissues, specifically in small animals. In a recent paper presented at the 2022 SPIE medical imaging conference, Nancy Ford and Ming Tan from the University of British Columbia presented data on the non-toxic Fenestra HDVC contrast agent showing the time course of contrast enhancement in various organs and the iodine dose. The new formulation of Fenestra was shown to have double the concentration of iodine (100mg/ml) compared to previous iterations. This allows researchers to reduce the injected dose, avoiding damage to the vasculature of the rodent.
The Fenestra HDVC provides substantial blood pool contrast enhancement instantaneously after injection, allowing immediate imaging of the vasculature. Within a few hours, the lipid-based contrast agent migrates to the liver and remains there for two weeks. This formulation provides longitudinal liver imaging after a single injection by selectively targeting hepatocytes providing a micro-CT contrast enhancement in the liver and the ability to delineate liver blood vessels.
With this lipid-based reagent, the liver achieved peak enhancement levels 48 hours after injection and the kidney reached peak levels 24 hours post-injection. However, there is enhanced vasculature immediately after injection for 8 hours. Since the contrast agent remains in the liver for 2 weeks, the subject avoids being re-injected but still allows them to be imaged multiple times making it a safer option.
Reference publication : Proceedings Volume 12036, Medical Imaging 2022: Biomedical Applications in Molecular, Structural, and Functional Imaging; 1203623 (2022) https://doi.org/10.1117/12.2611237
Event: SPIE Medical Imaging, 2022, San Diego, California, United States